UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
Amendment No. 2
| [X] | ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||
For the fiscal year endedJune 30, 2011
| ||||
| [ ] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT | |||
For the transition period from _________ to ________
| ||||
| Commission file number: 333-168930 | ||||
| Nano Mobile Healthcare, Inc. | |
| (Exact name of registrant as specified in its charter) | |
| Nevada | 93-0659770 |
(State or other jurisdiction of incorporation or organization)
| (I.R.S. Employer Identification No.) |
3 Columbus Circle, 15th Floor New York, NY |
10019 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number:917-745-72022
| |
Securities registered under Section 12(b) of the Exchange Act:
| |
| Title of each class | Name of each exchange on which registered |
| none | not applicable |
Securities registered under Section 12(g) of the Exchange Act:
| |
| Common Stock, Par Value $0.001 per Share | |
| (Title of each class) | |
| Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. |
| Yes [ ] No [X] |
| Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. |
| Yes [ ] No [X] |
| Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. |
| Yes [X] No [ ] |
| 1 |
| Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. | ||||||||
| Yes [X] No [ ] | ||||||||
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. | ||||||||
| [ ] | Accelerated filer | [ ] | ||||||
| [ ] | Smaller reporting company | [X] | ||||||
| Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). | ||||||||
| Yes [ ] No [X] | ||||||||
| State the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date. 74,250,000 issued and outstanding as of September 30, 2011. | ||||||||
| DOCUMENTS INCORPORATED BY REFERENCE: None. | ||||||||
| 2 |
EXPLANATORY NOTE
Nano Mobile Healthcare, Inc. (the "Company") is filing this Amendment No.2 of Form 10-K/A (this "Amendment") to amend its Annual Report on Form 10-K for the year ended June 30, 2011 (the "Original Form 10-K"), originally filed with the Securities and Exchange Commission on October 13, 2011, and later amended on November 21, 2011. The purpose of this Amendment is solely to correct a typographical error which appeared on the cover page of the Original Form 10-K, and was reproduced in the Company’s amendment to the Original Form 10-K, which incorrectly identified the Company as a shell company. The Company is making this Amendment to properly check the box that says “No,” the Company is not a shell company as defined in Rule 12b-2 of the Exchange act.
No revisions are being made to the Company's financial statements. This Amendment speaks as of the original filing date, does not reflect events occurring after the filing of the Original Form 10-K or subsequent amendment, or modify or update those disclosures that may be affected by subsequent events, and no other changes are being made to any other disclosure contained in the Original Form 10-K.
| 3 |
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENTS SCHEDULES
| (a) | Financial Statements and Schedules |
Financial Statements (See Item 8)
| (b) | Exhibits |
| 3.1 | Articles of Incorporation (1) | |
| 3.2 | By-laws (1) | |
| 31.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (2) | |
| 31.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (2) | |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (2) | |
| (1) | Incorporated by reference to the Form. S-1 filed with the Securities and Exchange Commission on August 19, 2010. | |
| (2) | Filed herein. | |
| 4 |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Nano Mobile Healthcare, Inc.
By: /s/ Joseph C. Peters
Joseph C. Peters
President, Chief Executive Officer, Principal Executive Officer,
Chief Financial Officer, Principal Financial Officer,
Principal Accounting Officer, and Director
October 28, 2016
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By: /s/ Joseph C. Peters
Joseph C. Peters
President, Chief Executive Officer, Principal Executive Officer,
Chief Financial Officer, Principal Financial Officer,
Principal Accounting Officer, and Director
October 28, 2016
By: /s/ Tony van Bijleveld
Tony van Bijleveld
Director
October 28, 2016
By: /s/ Dr. Steven R. Steinhubl
Steven R. Steinhubl
Director
October 28, 2016
| 5 |
